CAT extends DRC offer again
March 28 2002 - 1:00AM
UK Regulatory
RNS Number:7407T
Cambridge Antibody Tech Group PLC
28 March 2002
02/CAT/15
Not for release in Australia, Japan and the Republic of Ireland
FOR IMMEDIATE RELEASE
22.00 GMT 17.00 EST Wednesday 27 March 2002
For Further Information Contact:
Cambridge Antibody Technology Weber Shandwick Square Mile (Europe)
Tel: +44 (0) 1763 263 233 Tel: +44 (0) 20 7950 2800
John Aston, Finance Director Kevin Smith
Rowena Gardner, Head of Corporate Graham Herring
Communications
BMC Communications/The Trout Group (USA)
Tel: 001 212 477 9007
Brad Miles, ext 17 (media)
Brandon Lewis, ext.15 (investors)
CAMBRIDGE ANTIBODY TECHNOLOGY FURTHER EXTENDS OFFER FOR DRUG ROYALTY CORPORATION
TO 26 APRIL 2002
Melbourn, UK and Toronto, Canada... Cambridge Antibody Technology Group plc
("CAT") (LSE: CAT; NASDAQ: CATG) announced today that it has extended its offer,
through its wholly-owned subsidiary 3982904 Canada Inc., to acquire all of the
outstanding common shares of Drug Royalty Corporation Inc. ("DRC") (TSE: DRI) to
9.00 pm (EST) on Friday 26 April 2002. A formal notice of the extension of the
offer will be mailed as soon as is practicable.
-ENDS-
This information is provided by RNS
The company news service from the London Stock Exchange
Catco Reinsurance Opport... (LSE:CAT)
Historical Stock Chart
From Sep 2024 to Oct 2024
Catco Reinsurance Opport... (LSE:CAT)
Historical Stock Chart
From Oct 2023 to Oct 2024